Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks
A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.
Tag Archives: Rheumatoid Arthritis
-
-
Xeljanz Infection Risk Higher Than TNF Inhibitors: Study
Xeljanz use carries a higher infection risk than other arthritis drugs, like Humira, according to the findings of a new study.
-
Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study
A new study links Xeljanz and similar drugs to an increased risk of skin cancer.
-
Xeljanz Stroke Lawsuit Filed Against Pfizer for Gross Negligence in Failing to Warn About Drug Risks
A Xeljanz stroke lawsuit claims Pfizer failed to adequately warn about the drug's heart risks.
-
Rheumatoid Arthritis Risk Linked to Air Pollution Exposure
A new study links air pollution exposure to an increased risk of autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease.
-
Acthar Settlement Results in $260M Payment to Resolve DOJ Fraud and Illegal Kickback Allegations
Mallinckrodt will pay $260 million to resolve illegal Medicaid fraud and kickback claims brought against it by whistleblowers and the federal government over its marketing of Acthar gel.
-
Xeljanz Lawsuit Filed Over Failure to Warn About Risk of Blood Clots, Pulmonary Embolisms
A Xeljanz lawsuit claims Pfizer misled the public about the safety of the rheumatoid arthritis drug, leading to a man suffering a life-threatening blood clot.
-
Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks
A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing…
-
Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks
The FDA has approved Rinvoq for the treatment of atopic dermatitis despite cancer and heart problem fears.
-
Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings
The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.